Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Early Phase 1

Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma

NCT02245997 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to give 12T a smaller dose of radiation in order to decrease these late side effects.

Conditions Studied

Interventions

  • RADIATION External beam radiotherapy
  • RADIATION proton beam RT

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center — New York

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2014-09
Est. Completion 2025-05-01
Phase Early Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

2,280 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02245997

The ClinicalTrials.gov registry entry for NCT02245997 describes a study currently listed as completed. It is categorized as Early Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 2,280 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 2 interventions — of which External beam radiotherapy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02245997 reports 1 study location spanning 1 distinct geographic area — top geographies include New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02245997 about?

NCT02245997 is a clinical study titled "Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma". The purpose of this study is to give 12T a smaller dose of radiation in order to decrease these late side effects.

What is the current status of trial NCT02245997?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 78 participants. The study started on 2014-09. Estimated completion is 2025-05-01.

What conditions does trial NCT02245997 study?

This clinical trial studies the following conditions: Neuroblastoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02245997?

The interventions under investigation include: External beam radiotherapy (RADIATION), proton beam RT (RADIATION). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02245997?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 2,280 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02245997 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial